Patents by Inventor Juha Rouvinen
Juha Rouvinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11679152Abstract: The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.Type: GrantFiled: January 4, 2019Date of Patent: June 20, 2023Assignee: Desentum OyInventors: Juha Rouvinen, Kristiina Takkinen, Marja-Leena Laukkanen, Merja Niemi, Janne Jänis, Jaana Haka
-
Patent number: 11578125Abstract: The present invention relates to the fields of antibodies, antigen binding fragments and immunodiagnostics. Specifically, the invention relates to a recombinant anti-body or antigen binding fragment for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Also, the present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the recombinant antibody or antigen binding fragment of the present invention, as well as an ex-pression vector and host cell comprising the nucleic acid molecule of the present invention. Still, the present invention relates to a method of producing a recombi-nant antibody or antigen binding fragment for binding T4 thyroid hormone and hal-ogenated bisphenol A, a test kit and an immunoassay comprising the recombinant antibody or antigen binding fragment of the present invention, and a method for determining T4 thyroid hormone and/or halogenated bisphenol A levels in a sam-ple of a subject.Type: GrantFiled: May 28, 2019Date of Patent: February 14, 2023Assignees: Teknologian tutkimuskeskus VTT Oy, Politecnico di MilanoInventors: Tarja Nevanen, Henri Arola, Antti Tullila, Juha Rouvinen, Tarja Parkkinen, Pierangelo Metrangolo
-
Publication number: 20210230270Abstract: The present invention relates to the fields of antibodies, antigen binding fragments and immunodiagnostics. Specifically, the invention relates to a recombinant anti-body or antigen binding fragment for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Also, the present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the recombinant antibody or antigen binding fragment of the present invention, as well as an ex-pression vector and host cell comprising the nucleic acid molecule of the present invention. Still, the present invention relates to a method of producing a recombi-nant antibody or antigen binding fragment for binding T4 thyroid hormone and hal-ogenated bisphenol A, a test kit and an immunoassay comprising the recombinant antibody or antigen binding fragment of the present invention, and a method for determining T4 thyroid hormone and/or halogenated bisphenol A levels in a sam-ple of a subject.Type: ApplicationFiled: May 28, 2019Publication date: July 29, 2021Applicants: Teknologian tutkimuskeskus VTT Oy, Politecnico di MilanoInventors: Tarja NEVANEN, Henri AROLA, Antti TULLILA, Juha ROUVINEN, Tarja PARKKINEN, Pierangelo METRANGOLO
-
Publication number: 20200345839Abstract: The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.Type: ApplicationFiled: January 4, 2019Publication date: November 5, 2020Inventors: Juha Rouvinen, Kristiina Takkinen, Marja-Leena Laukkanen, Merja Niemi, Janne Jänis, Jaana Haka
-
Patent number: 9856296Abstract: The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.Type: GrantFiled: April 18, 2012Date of Patent: January 2, 2018Assignee: DESENTUM OYInventors: Kristiina Takkinen, Marja-Leena Laukkanen, Hans Söderlund, Sirpa Jylhä, Heidi Holkeri, Merja Niemi, Janne Jänis, Juha Rouvinen
-
Patent number: 9261511Abstract: The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in ?-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy.Type: GrantFiled: January 29, 2008Date of Patent: February 16, 2016Assignee: DESENTUM OYInventors: Sirpa Jylhä, Merja Niemi, Juha Rouvinen, Marja-Leena Laukkanen, Kristiina Takkinen, Hans Söderlund, Soili Mäkinen-Kiljunen, Tari Haahtela
-
Patent number: 8877894Abstract: The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified ?-lactoglobulins for use in immunotherapy of milk allergy.Type: GrantFiled: June 18, 2009Date of Patent: November 4, 2014Assignee: Teknologian Tutkimuskeskus VTTInventors: Juha Rouvinen, Kristiina Takkinen, Merja Niemi, Sirpa Jylhä, Hans Söderlund, Marja-Leena Laukkanen
-
Publication number: 20140044744Abstract: The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicant: TEKNOLOGIAN TUTKIMUSKESKUS VTTInventors: Kristiina Takkinen, Marja-Leena Laukkanen, Hans Söderlund, Sirpa Jylhä, Heidi Holkeri, Merja Niemi, Juha Rouvinen
-
Publication number: 20140037663Abstract: The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.Type: ApplicationFiled: April 18, 2012Publication date: February 6, 2014Applicant: TEKNOLOGIAN TUTKIMUSKESKUS VTTInventors: Kristiina Takkinen, Marja-Leena Laukkanen, Hans Söderlund, Sirpa Jylhä, Heidi Holkeri, Merja Niemi, Janne Jänis, Juha Rouvinen
-
Publication number: 20110104190Abstract: The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified ?-lactoglobulins for use in immunotherapy of milk allergy.Type: ApplicationFiled: June 18, 2009Publication date: May 5, 2011Applicant: TEKNOLOGIAN TUTKIMUSKESKUS VTTInventors: Juha Rouvinen, Kristiina Takkinen, Merja Niemi, Sirpa Jylhä, Hans Söderlund, Marja-Leena Laukkanen
-
Publication number: 20100311604Abstract: This invention relates to protein engineering technology. More particularly, the present invention relates to a method for preparing human IgE antibodies and derivatives thereof, which bind epitope structures that are weakly IgG or IgM immunoreactive.Type: ApplicationFiled: January 29, 2008Publication date: December 9, 2010Applicant: Valtion Teknillinen TutkimuskeskusInventors: Kristiina Takkinen, Juha Rouvinen, Merja Niemi, Sirpa Jylhä, Marja-Leena Laukkanen, Hans Söderlund
-
Publication number: 20100086552Abstract: The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in ?-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy.Type: ApplicationFiled: January 29, 2008Publication date: April 8, 2010Applicant: Valtion Teknillinen TutkimuskeskusInventors: Sirpa Jylhä, Merja Niemi, Juha Rouvinen, Marja-Leena Laukkanen, Kristiina Takkinen, Hans Söderlund, Soili Mäkinen-Kiljunen, Tari Haahtela